Mohamad Ghazi Sinno

Mohamad Ghazi Sinno

Auto-generated profile, based on publicly available information

Mohamad Ghazi Sinno

36Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, AZ

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2017 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
Sherif M. BadawySherif M. Badawy
Sherif M. Badawy
LBLeonardo Barrera
Leonardo Barrera
MSMohamad G Sinno
Mohamad G Sinno
SKSaara Kaviany
Saara Kaviany
LOLinda C O’dWyer
Linda C O’dWyer
LKLisa Kuhns
Lisa Kuhns
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

16 February 2023 in Blood
Verified
Journal Article
Closed access
PDF file
SESarah Elitzur
Sarah Elitzur
AVAjay Vora
Ajay Vora
BBBirgit Burkhardt
Birgit Burkhardt
HIHiroto Inaba
Hiroto Inaba
AAAndishe Attarbaschi
Andishe Attarbaschi
KSKjeld Schmiegelow
Kjeld Schmiegelow
The development of a second malignancy after the diagnosis of childhood acute lymphoblastic leukemia (ALL) is a rare event. Certain second malignancies have been linked with specific elements of leukemia therapy, yet the etiology of most second neoplasms remains obscure and their optimal management strategies are unclear. This is a first comprehensive report of non-Hodgkin lymphomas (NHLs) following pediatric ALL therapy, excluding stem-cell transplantation. We analyzed data of patients who developed NHL following ALL diagnosis and were enrolled in 12 collaborative pediatric ALL trials between 1980-2018. Eighty-five patients developed NHL, with mature B-cell lymphoproliferations as the dominant subtype (56 of 85 cases). Forty-six of these 56 cases (82%) occurred during or within 6 months of maintenance therapy. The majority exhibited histopathological characteristics associated with immunodeficiency (65%), predominantly evidence of Epstein-Barr virus–driven lymphoproliferation. We investigated 66 cases of post-ALL immunodeficiency-associated lymphoid neoplasms, 52 from our study and 14 additional cases from a literature search. With a median follow-up of 4.9 years, the 5-year overall survival for the 66 patients with immunodeficiency-associated lymphoid neoplasms was 67.4% (95% confidence interval [CI], 56-81). Five-year cumulative risks of lymphoid neoplasm– and leukemia-related mortality were 20% (95% CI, 10.2-30) and 12.4% (95% CI, 2.7-22), respectively. Concurrent hemophagocytic lymphohistiocytosis was associated with increased mortality (hazard ratio, 7.32; 95% CI, 1.62-32.98; P = .01). A large proportion of post-ALL lymphoid neoplasms are associated with an immunodeficient state, likely precipitated by ALL maintenance therapy. Awareness of this underrecognized entity and pertinent diagnostic tests are crucial for early diagnosis and optimal therapy.